Furthermore, neutralization of SDF-1 by anti-SDF-1 or anti-CXCR4 monoclonal antibody in pre-clinical studies results in a significant decrease of NSCLC metastases [21]. This evidence concerns the gene CXCR4 and non-small cell lung carcinoma.